A-share

UP Fintech Holding Limited to be Added to the MSCI China All Shares Index

Retrieved on: 
Thursday, May 13, 2021
Economy, MSCI, Morgan Stanley, Financial markets, Companies, Index, A-share, Shenzhen

Wu Tianhua, CEO of UP Fintechcommented, "To be added to the MSCI China All Shares Index is a recognition of the company\'s growth achievement.

Key Points: 
  • Wu Tianhua, CEO of UP Fintechcommented, "To be added to the MSCI China All Shares Index is a recognition of the company\'s growth achievement.
  • As we expand our international footprint, we look forward to serving more global clients with our intuitive, one-stop trading platform.
  • "\nAccording to MSCI, "The MSCI China All Shares Index captures large and mid-cap representation across China Ashares, Bshares, Hshares, Redchips, Pchips and foreign listings (e.g.
  • The index aims to reflect the opportunity set of China share classes listed in Hong Kong, Shanghai, Shenzhen and outside of China.

The first A+H+G insurance company is ready to embark on its journey: CPIC discloses intention to float at the London Stock Exchange

Retrieved on: 
Thursday, June 11, 2020
Companies, Finance, Economy, Stock Connect, UBS, China Pacific Insurance Company, A-share

Post the completion of the issuance, China Pacific Insurance will be the first Chinese insurer to list simultaneously in Shanghai, Hong Kong and London.

Key Points: 
  • Post the completion of the issuance, China Pacific Insurance will be the first Chinese insurer to list simultaneously in Shanghai, Hong Kong and London.
  • According to the Intention to Float, China Pacific Insurance intends to issue up to 113,160,600 GDRs with each GDR representing 5 A shares of the company.
  • The GDR issued is expected to be listed in the UK and traded on the Shanghai-London Stock Connect segment of the Main Market of the London Stock Exchange.
  • UBS AG London Branch and Huatai Financial Holdings (Hong Kong) Limited are acting as Joint Global Co-ordinators and Joint Bookrunners for this issuance.

Junshi Biosciences Announces Approval of Proposed A-Share Listing by the Listing Committee for the Shanghai Stock Exchange (SSE) STAR Market

Retrieved on: 
Tuesday, March 31, 2020
Financial markets, Finance in China, Economy, Finance, Futures exchanges, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, China Securities Regulatory Commission, Hong Kong Stock Exchange, A-share

SHANGHAI, China, March 30, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today the approval of its proposed A-share listing by the Listing Committee for the Shanghai Stock Exchange (SSE) STAR Market.

Key Points: 
  • SHANGHAI, China, March 30, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today the approval of its proposed A-share listing by the Listing Committee for the Shanghai Stock Exchange (SSE) STAR Market.
  • On March 30, 2020, the application for the Proposed A-Share Listing of the Company was approved at the Seventh Meeting of the Listing Committee of the STAR Market Stock Listing Committee for 2020.
  • The Proposed A-Share Listing is subject to approval of registration by the China Securities Regulatory Commission (CSRC).
  • On December 24, 2018, Junshi Biosciences was listed on the Main Board of the Stock Exchange of Hong Kong with the stock code: 1877.HK.

Pharmaron Lists H-Shares on the Hong Kong Stock Exchange

Retrieved on: 
Thursday, November 28, 2019
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Finance in China, Economy of China, Economy, A-share, H share, Hong Kong Stock Exchange

Pharmaron Beijing Co., Ltd. (Stock Code: 300759.SZ/3759.HK) announced today that 117 million H-shares are listed on the Main Board of The Stock Exchange of Hong Kong.

Key Points: 
  • Pharmaron Beijing Co., Ltd. (Stock Code: 300759.SZ/3759.HK) announced today that 117 million H-shares are listed on the Main Board of The Stock Exchange of Hong Kong.
  • The successful listing of H-shares on The Stock Exchange of Hong Kong, together with the existing A-shares listing on the Shenzhen Stock Exchange (A+H dual listing), has broadened Pharmarons financing channels to support its global growth strategy.
  • With the strong financial support, Pharmaron will continuously strengthen its service capabilities and capacities by integrating cutting-edge science and technologies into the existing service platforms.
  • Our listing on The Stock Exchange of Hong Kong marks another milestone for Pharmaron, said Dr. Boliang Lou, Chairman and CEO, Pharmaron.

Salesforce Completes Exchange Offer for MuleSoft Common Stock

Retrieved on: 
Wednesday, May 2, 2018
Finance, Economy, Money, Stock market, Cloud applications, Corporate finance, Equity securities, salesforce.com, MuleSoft, Stock, Common stock, A-share

SAN FRANCISCO, May 2, 2018 /PRNewswire/ --Salesforce (NYSE: CRM), the global leader in CRM, today announced the successful completion of its previously announced exchange offer for all of the outstanding shares of Class A common stock and Class B common stock of MuleSoft, Inc. ("MuleSoft"), at a per share price of $36.00 in cash and 0.0711 of a share of Salesforce common stock, together with cash in lieu of any fractional shares of Salesforce common stock, without interest and less any applicable withholding taxes.

Key Points: 
  • SAN FRANCISCO, May 2, 2018 /PRNewswire/ --Salesforce (NYSE: CRM), the global leader in CRM, today announced the successful completion of its previously announced exchange offer for all of the outstanding shares of Class A common stock and Class B common stock of MuleSoft, Inc. ("MuleSoft"), at a per share price of $36.00 in cash and 0.0711 of a share of Salesforce common stock, together with cash in lieu of any fractional shares of Salesforce common stock, without interest and less any applicable withholding taxes.
  • As of the expiration of the exchange offer, a total of approximately 74,639,665 shares of Class A common stock of MuleSoft and 37,210,949 shares of Class B common stock of MuleSoft were validly tendered in the exchange offer and not validly withdrawn, representing approximately 83% of the aggregate voting power of the shares of MuleSoft common stock outstanding immediately after the consummation of the exchange offer.
  • All shares that were validly tendered and not validly withdrawn have been accepted by Salesforce for payment in accordance with the terms of the exchange offer.
  • Each remaining share of Class A common stock and Class B common stock of MuleSoft not purchased in the exchange offer (other than shares held in the treasury of MuleSoft and any shares owned by Salesforce, MuleSoft or any of their respective subsidiaries and shares held by any MuleSoft stockholder who has validly exercised its appraisal rights under the General Corporation Law of the State of Delaware) was converted into the right to receive the same $36.00 in cash and 0.0711 of a share of Salesforce common stock, together with cash in lieu of any fractional shares of Salesforce common stock, without interest and less any applicable withholding taxes, that will be paid in the exchange offer.